Response to comment on Ohkuma et al. Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: The ADVANCE trial. Diabetes care 2017;40:1203-1209

Toshiaki Ohkuma, Mark Woodward, John Chalmers, ADVANCE Collaborative Group

Research output: Contribution to journalLetter

Abstract

We would like to thank Dr. Kawada for the comments (1) on our paper (2).
First, we agree that the use of biomarkers is beneficial for early detection of heart failure and prevention of subsequent other cardiovascular diseases.
Second, we agree with the need for careful monitoring of the incidence of cardiovascular diseases other than heart failure, as heart failure is the second most common initial presentation of cardiovascular disease in patients with type 2 diabetes after peripheral arterial disease (3).
Third, we agree with the possible influence of glycemic control on the incidence of heart failure. As cited by Dr. Kawada, intensive glucose-lowering therapy significantly decreased the risk of a composite of major cardiovascular events including heart failure in the Veterans Affairs Diabetes Trial (VADT) (4). Although a later meta-analysis of randomized controlled trials including the VADT found that the intensive glucose-lowering treatment did not decrease the risk of heart failure (5), we included randomized blood pressure–lowering intervention as well as HbA1c as covariates, given the possible confounding of these factors.
inally, we agree that electrocardiogram findings were important for the risk prediction of heart failure and thus included them in the model as covariates. However, as the primary objective of our paper was to examine the predictive ability of biomarkers for heart failure, we did not test the prognostic ability of the combination of electrocardiogram findings and biomarkers. We also agree that there is a possible adverse effect for heart failure of medication such as dipeptidyl peptidase 4 inhibitors used to treat type 2 diabetes. However, dipeptidyl peptidase 4 inhibitors were not on the market when the ADVANCE trial started.
Original languageEnglish
Pages (from-to)e39
Number of pages1
JournalDiabetes Care
Volume41
Issue number3
DOIs
Publication statusPublished - 1 Mar 2018
Externally publishedYes

Keywords

  • Biomarkers
  • Heart failure
  • Type 2 diabetes
  • Cardiovascular disease
  • Monitoring

Fingerprint Dive into the research topics of 'Response to comment on Ohkuma et al. Cardiac stress and inflammatory markers as predictors of heart failure in patients with type 2 diabetes: The ADVANCE trial. Diabetes care 2017;40:1203-1209'. Together they form a unique fingerprint.

  • Cite this